Bonn - Köln

München Tübingen Heidelberg Giessen – Marburg – Langen Bonn – Köln Hannover – Braunschweig Hamburg – Lübeck Borstel – Riems
Research areas

At Bonn - Köln a concentration of activities has been achieved in relation to the research and development of new antibiotics. In cooperation with the Translational Project Management Office (TPMO) and the Federal Institute for Drugs and Medical Devices (BfArM) within the Product Development Unit, the preclinical development of the new antibiotic Corallopyronin A continues to have high priority for the Bonn - Köln site. In the vaccine research, vaccines against bacterial pathogens like S. aureus and A. baumannii are developed into the clinical application phase. Scientists in the research field Healthcare-associated and Antibiotic-resistant bacterial Infections research bacterial colonisations and infections with multidrug- resistant bacteria with regard to both type and prevalence, as well as treatment options and the effectiveness of infection control measures. In HIV research, the scientists bring new antibody mediated treatment approaches into translation. In addition, SARS-CoV-2 research at the Bonn - Köln site is also a top priority. The site also coordinates the DZIF Clinical Trial Unit.